Dr Van Tine on Investigating Cabozantinib With PD-1 and CTLA-4 Inhibition in Sarcoma
June 9th 2023Brian A. Van Tine, MD, PhD, discusses the rationale for launching a randomized phase 2 trial investigating cabozantinib combined with nivolumab and ipilimumab vs cabozantinib alone in metastatic soft tissue sarcoma and discusses key findings from the trial.
Read More
Dr Van Tine on the Investigation of KB-0742 in R/R Solid Tumors
June 6th 2023Brian A. Van Tine, MD, PhD, discusses the ongoing evaluation of the CDK9 inhibitor KB-0742 in a phase 1 trial in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma, detailing the key enrollment criteria.
Read More
Dr. Van Tine on the Methods Utilized in the Spearhead 1 Trial in Sarcoma Subtypes
February 10th 2022Brian A. Van Tine, MD, PhD, discusses the methods utilized in the phase 2 Spearhead 1 trial evaluating afamitresgene autoleucel in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.
Read More
Academic Medical Oncologists Complement Role of Community Oncologists in Sarcoma Treatment
October 24th 2013One of the privileges of working in an academic medical center is the luxury of being able to subspecialize in the treatment of sarcoma. Nationwide, there may be 40 to 50 medical oncologists who focus on the treatment of adult soft tissue and bone sarcoma.
Read More